Latest News & Articles

  • 6 November 2015

    The line between a successful parody and a fraudulent imitation may be a fine one. If attempting to poke fun at another trader’s trade mark or name, be careful that you do not fall on the wrong side of that line.

  • 6 November 2015

    A number of trade mark issues have arisen during negotiations for the Trans Pacific Partnership Agreement (TPP). In this article we pick up on three of these issues, and explain what protections are available in New Zealand for non-traditional trade marks (such as trade marks for shapes, sounds and smells), well known marks and geographical indications.

  • 7 October 2015

    In a landmark decision handed down 7 October 2015, the High Court of Australia has reversed the decisions of the lower courts and found that isolated genetic material is not patentable subject matter.

    In D'Arcy v Myriad Genetics Inc [2015] HCA 35 the High Court of Australia unanimously held that claims 1 to 3 of Australian Patent No. 686004 did not relate to patentable subject matter and so were invalid

  • 6 October 2015

    The trade ministers of the 12 countries who are party to the negotiations have announced that the terms of the Trans-Pacific Partnership (TPP) have been agreed.

    The TPP is a multi-national free trade agreement, between Australia, Brunei Darussalam, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, the United States and Vietnam, which together represent approximately 40% of the world’s GDP. It is the most significant multi-lateral free trade agreement since the Uruguay round of the WTO.

  • 19 August 2015

    Our recent articles have summarised the issues surrounding the Trans-Pacific Partnership (TPP) negotiations relating to pharmaceuticals and patent protection, and trade marks and geographical indications. Another issue which has received attention is the potential impact of any TPP agreement on the patentability of computer software.

  • 12 August 2015

    Following the latest round of Trans-Pacific Partnership (TPP) negotiations in Hawaii, there has been a significant public interest in pharmaceutical patents. In this article we attempt to clarify and/or correct some of the information that is available in the draft Intellectual Property (IP) Chapter of the TPP agreement as it applies to pharmaceuticals[1]. In particular we discuss the distinction between patent protection (and patent term extension) for pharmaceuticals, data protection and patent linkage, the proposals for each, and where the current law in New Zealand stands in relation to these proposals.


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

MoST Content Management V3.0.8886